Biblio
“Serum C-Peptide, Visfatin, Resistin, and Ghrelin are Altered in Sporadic and GRN-Associated Frontotemporal Lobar Degeneration.”, J Alzheimers Dis, vol. 61, no. 3, pp. 1053-1060, 2018.
, “Assay of Plasma Phosphorylated Tau Protein (Threonine 181) and Total Tau Protein in Early-Stage Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1323-1332, 2018.
, “Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1045-56, 2016.
, “11C-CFT-PET in Presymptomatic FTDP-17: A Potential Biomarker Predicting Onset.”, J Alzheimers Dis, vol. 61, no. 2, pp. 613-618, 2018.
, “Soluble TREM2, Alzheimer's Disease Pathology, and Risk for Progression of Cerebral Small Vessel Disease: A Longitudinal Study.”, J Alzheimers Dis, vol. 92, no. 1, pp. 311-322, 2023.
, “tRNA-Derived Fragments in Alzheimer's Disease: Implications for New Disease Biomarkers and Neuropathological Mechanisms.”, J Alzheimers Dis, vol. 79, no. 2, pp. 793-806, 2021.
, “Circulating microRNAs as Biomarkers of Alzheimer's Disease: A Systematic Review.”, J Alzheimers Dis, vol. 49, no. 3, pp. 755-66, 2016.
, “Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer's Disease.”, J Alzheimers Dis, vol. 92, no. 1, pp. 95-107, 2023.
, “Evaluation of Cerebrospinal Fluid Assay Variability in Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 2, pp. 463-70, 2016.
, “Rationale and Design of the Mechanistic Potential of Antihypertensives in Preclinical Alzheimer's (HEART) Trial.”, J Alzheimers Dis, vol. 61, no. 2, pp. 815-824, 2018.
, “Bridging Integrator 1 (BIN1) Genotypes Mediate Alzheimer's Disease Risk by Altering Neuronal Degeneration.”, J Alzheimers Dis, vol. 52, no. 1, pp. 179-90, 2016.
, “Prevention Trials in Alzheimer's Disease: Current Status and Future Perspectives.”, J Alzheimers Dis, vol. 50, no. 4, pp. 927-45, 2016.
, “A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1541-1553, 2018.
, “Rheumatoid Arthritis, Cognitive Impairment, and Neuroimaging Biomarkers: Results from the Mayo Clinic Study of Aging.”, J Alzheimers Dis, vol. 89, no. 3, pp. 943-954, 2022.
, “Structural Connectivity Alterations Along the Alzheimer's Disease Continuum: Reproducibility Across Two Independent Samples and Correlation with Cerebrospinal Fluid Amyloid-β and Tau.”, J Alzheimers Dis, vol. 61, no. 4, pp. 1575-1587, 2018.
, “Alterations in Acrolein Metabolism Contribute to Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 2, pp. 571-580, 2018.
, “Understanding the Involvement of microRNAs in Mitochondrial Dysfunction and Their Role as Potential Biomarkers and Therapeutic Targets in Parkinson's Disease.”, J Alzheimers Dis, vol. 94, no. s1, pp. S187-S202, 2023.
, “Is the Frontal Lobe the Primary Target of SARS-CoV-2?”, J Alzheimers Dis, vol. 81, no. 1, pp. 75-81, 2021.
, “Dementia and COVID-19, a Bidirectional Liaison: Risk Factors, Biomarkers, and Optimal Health Care.”, J Alzheimers Dis, vol. 82, no. 3, pp. 883-898, 2021.
, “Functional Neurophysiological Biomarkers of Early-Stage Alzheimer's Disease: A Perspective of Network Hyperexcitability in Disease Progression.”, J Alzheimers Dis, vol. 88, no. 3, pp. 809-836, 2022.
, “Association of Interleukin-6 and Interleukin-8 with Cognitive Decline in an Asian Memory Clinic Population.”, J Alzheimers Dis, vol. 92, no. 2, pp. 445-455, 2023.
, “Association of Cholinergic Basal Forebrain Volume and Functional Connectivity with Markers of Inflammatory Response in the Alzheimer's Disease Spectrum.”, J Alzheimers Dis, vol. 85, no. 3, pp. 1267-1282, 2022.
, “Pramlintide: The Effects of a Single Drug Injection on Blood Phosphatidylcholine Profile for Alzheimer's Disease.”, J Alzheimers Dis, vol. 62, no. 2, pp. 597-609, 2018.
, “Plasma Soluble ST2 Levels Are Higher in Neurodegenerative Disorders and Associated with Poorer Cognition.”, J Alzheimers Dis, vol. 92, no. 2, pp. 573-580, 2023.
, “Tauopathies: Mechanisms and Therapeutic Strategies.”, J Alzheimers Dis, vol. 61, no. 2, pp. 487-508, 2018.
,